Background: Although multiple medications havebeen studied for the treatment of cocaine dependence, nomedication has been shown to have a robust effect on craving anduse. This pilot project was designed to evaluate the safety andtolerability of gabapentin in subjects with cocaine dependence.
Method: Thirty cocaine-dependent subjects(DSM-IV criteria) were enrolled in an 8-week, open-label trial of1200 mg/day of gabapentin in divided doses. Urine drug screens,subjective measures of craving, and cocaine use interviews wereconducted at each weekly visit.
Results: Baseline rating of amount and frequencyof craving decreased significantly by week 8 (78% vs. 25% foramount, p = .000; 74% vs. 23% for frequency, p = .004). Positiveurine drug screens for cocaine decreased from 86% at baseline to29% at weeks 4 and 8. There were no reports of significant sideeffects or adverse events.
Conclusion: This pilot study indicates thatgabapentin is safe and well tolerated and may be beneficial inthe treatment of cocaine dependence. A placebo-controlled trialwould be of interest.
Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
Please sign in or purchase this PDF for $40.00.
Save
Share
Cite
